🩸🚀 New Insights in Liquid Biopsy! 🧬 The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis. 🔗 Read the full article here www.journalofliquidbiopsy.com/article/S295...

🚨Excited to represent the @islb.info at #ASCO25! Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities! Got questions about the society? We’ve got answers. Come to connect!🩸 @ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

#TME in #NSCLC shapes therapy resistance and progression - a tumor can have two immune niches: rich and poor - more than immune cells: CAFs, TAMs, DCs, T, NK.. - patient-specific determinants modulate the TME 🔍emerging technologies www.nature.com/articles/s41...

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong. Could this combo help overcome resistance in more aggressive ALK variants? #research #lungcancer

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure. Overall population: - ORR 32% - CBR 69% - median DoR 11.2 mo 48% asian, 39% white. 9% discontinued due to side effects @oncoalert.bsky.social

📰EGFR-TKI resistance in LUAD isn’t always genetic. - 39 pts-derived organoids - 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss. - Knockout of NKX2-1 → basal-shift + Osim res - These tumors often lose CDKN2A/B pbs.twimg.com/media/Gq6QwX...

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial! ➡️12m OS 55 %  ➡️0 % ORR ➡️manageable safety profile @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala pmc.ncbi.nlm.nih.gov/articles/PMC...

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx. ➡️ #Tepotinib showed robust efficacy regardless of biopsy type @christianrolfo.bsky.social @oncoalert.bsky.social

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism” @OSUCCC_James @osuwexmed.bsky.social @christianrolfo.bsky.social @theaacr.bsky.social pbs.twimg.com/media/Gpay9i...

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬 LB is reshaping cancer care 💥 Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/ @islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬 Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social Exciting discussions shaping the future of #lungcancer testing! 📚

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅 Grateful for the chance to meet with exceptional people 👐 @stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

As always, an insightful presentation by @UmbertoMalapelle ➡️ "From single gene testing to CGP." 🔬✨ at #ELCC25 @myesmo.bsky.social We must continue this path to improve treatment selection! @islb.info #precisiononcology #lungcancer ⬇️ Key message

Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights! @osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social @unige

📢 5-year outcomes from EMPOWER-Lung 1: 1L cemiplimab vs chemo in PD-L1 high (≥50%) NSCLC! 👫🏻 565 pts; 1 vs 1 ✅ mOS favors cemiplimab: 26.1 vs 13.3m (HR 0.59), 38.8m in PD-L1 ≥90% ✅ PFS 8.1 vs 5.3m (HR 0.50) ✅ 5y OS rate: 29% vs 15% www.jto.org/article/S155... #Immunotherapy #NSCLC

What a great news! Finally we have a journal dedicated to liquid biopsy research! I am truly excited. 🔥

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸 Read more: doi.org/10.1016/j.crit…#LiquidBiopsysy @christianrolfo.bsky.social

🚨 Out in @natrevclinoncol.bsky.social 📌ctDNA helps uncover resistance mechanisms 📌Standardized protocols are crucial for improving applications 📌ctDNA + tissue provides a more comprehensive view nature.com/articles/s41... @christianrolfo.bsky.social @osucccjames.bsky.social

Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬 --> bit.ly/3DFSzLi Panelists: @christianrolfo.bsky.social #UmbertoMalapelle #YasushiYatabe #MervatMahrous Organizer: #touchOncology @rolfolab.bsky.social @oncoalert.bsky.social

Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer! @christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social ➡️ hubs.la/Q03bqnlB0

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer! @christianrolfo.bsky.social @rolfolab.bsky.social @osucccjames.bsky.social #HER2 #IHC #Targettherapy

✨ Insightful presentation by @manelesteller.bsky.social from @carrerasijc.bsky.social at @osuwexmed.bsky.social Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊 @christianrolfo.bsky.social @rolfolab.bsky.social

⏱️ To-do list for today: Tune in to the live webinar by @iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs! @christianrolfo.bsky.social @rolfolab.bsky.social www.iaslc.org/meetings-web...

Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊 #lungcancer #myESMO #DeepDiveLungCancer @christianrolfo.bsky.social @rolfolab.bsky.social ow.ly/vbSt50UPrrS

🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the #ISLB survey to help shape strategies for improving #liquidbiopsies in clinical oncology. Let’s advance precision care for medical oncologists together! 🩺🔬 @christianrolfo.bsky.social @rolfolab.bsky.social

When tissue is the issue! Great presentation by @christianrolfo.bsky.social at the XIII Molecular Cytopathology We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬 @ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1 @MariantoniaNac1

A great initiative by European School of Oncology to share clinical cases among oncologists! I had the possibility to discuss a geriatric breast cancer patients and how to handle specific “frail” situations! 👵🏻 Check the link! 🎯 bit.ly/e-ESO @unige

Honored to had the opportunity to present my experience on CAR-T cells that I did at @unclineberger.bsky.social at a seminar for PhD students at @Dipsanita_UniNa 💪 Such a great class! @UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social

Great VI Annual Meeting of the Pelotonia Instituteof Immuno Oncology @OhioStatePIIO with important participation and stellar faculty. Congrats @ZihaiLi and all the team! @OhioStateMedOnc @OhioStateMed @OSUCCC_James cancer.osu.edu/events/piio-...

Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist - 3211pts, ConcertAI database - 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4% - s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE @oncoalert.bsky.social #MedSky #OncSky #LCSM academic.oup.com/oncolo/advan...

@GianniNigita from @osucccjames.bsky.social @rolfolab.bsky.social presenting the minimal requirements for bioinformatics in analyzing liquid biopsy data at #ISLB24 More complex data —> more power bioinformatics required! 💻🤖 @christianrolfo.bsky.social @UmbertoMalapel1 @isliquidbiopsy

Honored to have @lillian_siu elected president of @AACR at the #ISLB24 meeting talking about HPV ctDNA! HPV genotyping in plasma may be the future! Truly inspiring 💪🏻🔥🎯 @isliquidbiopsy @christianrolfo.bsky.social @christianrolfo.bsky.social @UmbertoMalapel1

Second day at #ISLB24 with @christianrolfo.bsky.social presenting data on early cancer detection in different cancer types! —> is possible but there are many different LB 🩸 method that must be integrated with AI 🤖 @internationalsocietyofliquidbiopsy @ohiostatepress.bsky.social

@christianrolfo.bsky.social presenting at #ISLB24 early detection strategies for different cancers! 📚Many studies are being published in this topic What is the best strategy? —>a mix of different technologies 👨🏻‍🔬👩‍🔬 + AI integration! 🤖 @isliquidbiopsy @OSUCCC_James

🏆Award session and inspiring Award lectures! #LuisDiaz #EllenHeltzer #DennisLo #ISLB24 @isliquidbiopsy @christianrolfo.bsky.social @MJOSESERRANO19

🎯 @BrunaPellini just explained to me how their algorithm could help in distinguishing between variants identified via LB “truly/potentially” targetable vs CH-derived across different tumor types ⚡️ Great energy here! @isliquidbiopsy #ISLB24

❔❓Having expert to discuss key questions in liquid biopsy! This is #ISLB24 @isliquidbiopsy @christianrolfo.bsky.social #abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky

Great job by @Rparedes_MD presenting our poster on “ctDNA as marker for Brain Metastasis at Diagnosis and During Treatment” at #ISLB24 @rolfolab @isliquidbiopsy @OhioStateMedOnc @OSUCCC_James @IcahnMountSinai @TischCancer

Super @christianrolfo.bsky.social !

Super poster session! 🧨 @UmbertoMalapel1 shows us how an algorithm can filter out genomic alterations while analyzing LB sample in a prostate cancer cohort of patients! #ISLB24 @isliquidbiopsyhttps://x.com/RobertoBoreaMD/status/1860412702520205367/photo/1

Brilliant presentation by @christianrolfo.bsky.social from OSUCCC on ctDNA fragmentation in solid tumors! 🔑 message ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients! @umbertomalapelle1 @stoverlab.bsky.social

Terrific presentation of @christianrolfo.bsky.social from @OSUCCC_James on tumor fraction detection and calculation in cfDNA! 🧬 —> we must implement cfDNA fraction analysis to improve the comprehension of LB #ISLB24 @internationalsocietyofliquidbiopsy @UmbertoMalapel1 @stoverlab.bsky.social

Great presentation from @natashaleighl from @pmargaretcancercenter on the usage of molecular testing in cancer patients! 🥵 Hot topics: - timing ⏱️ - patient point of view 🫵 - type of test 🤷🏻‍♀️ - cost 💰 #ISLB24

LB 🩸 isn’t only for medical oncologist! @aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome! #ISLB24 @christianrolfo.bsky.social @rolfolab.bsky.social @isliquidbiopsy

Nice to meet great international colleagues/researchers at #ISLB24! 🌎 Ready for this great event to share knowledge about liquid biopsy! 🔥 @internationalsocietyofnliquidbiopsy @christianrolfo.bsky.social @umbertomalapelle @brunapellini @robertoboreamd.bsky.social @mariantonianacchio

The annual International Society of Liquid Biopsy #ISLB is starting now in Denver. No better way to celebrate the beginning of this event than with a picture of the president of ISLB @christianrolfo.bsky.social and the secretary of ISLB @umbertomalapelle Ready to kick of! 🩸🧬

Finally in Denver for the @isliquidbiopsy annual congress! 🩸 Thanks to ISLB commette for the Travel Grant Award ✈️ that allowed me to be here! Ready to dive in the LB world! 🔋Truly excited! @christianrolfo.bsky.social @rolfolab.bsky.social @UmbertoMalapel1 @MariantoniaNac1